Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxart, Inc.
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.
As vaccine development progresses, worldwide deaths caused by SARS-CoV-2 continue to rise, and now exceed 500,000, with more than 10 million confirmed cases. Daily new infections also hit a new peak, as some US states are being forced to consider lockdowns again as the situation worsens.
An inflection point arrives as US public sector pharma manufacturing hits 'warp speed' in COVID-19 crisis.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
- Drug Delivery
- Other Names / Subsidiaries
- Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
- Biota Holdings Limited
- Biota Pharmaceuticals, Inc.
- Nabi Biopharmaceuticals)